Holen Sie sich die Stockscreener-App
50.67
2.16%
1.1399
Schlusskurs vom Vortag:
$49.53
Offen:
$50.16
24-Stunden-Volumen:
3.46M
Relative Volume:
0.68
Marktkapitalisierung:
$9.06B
Einnahmen:
$1.27B
Nettoeinkommen (Verlust:
$-245.03M
KGV:
-36.01
EPS:
-1.4071
Netto-Cashflow:
$-245.36M
1W Leistung:
-3.18%
1M Leistung:
-2.60%
6M Leistung:
-41.42%
1J Leistung:
+20.00%
1-Tages-Spanne:
$49.70
$51.45
1-Wochen-Bereich:
$49.32
$53.63
52-Wochen-Spanne:
$36.22
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Firmenname
Tempus Ai Inc
Sektor
Branche
Telefon
800-976-5448
Adresse
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
50.68 | 8.85B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
VEEV
Veeva Systems Inc
|
179.44 | 29.72B | 3.20B | 908.91M | 1.42B | 5.4155 |
|
BTSG
Brightspring Health Services Inc
|
38.26 | 7.42B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
76.89 | 6.56B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
24.13 | 4.72B | 1.10B | 112.09M | 283.19M | 0.6096 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Mizuho | Outperform |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-21 | Eingeleitet | BTIG Research | Buy |
| 2025-02-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Fortgesetzt | TD Cowen | Buy |
| 2024-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-09 | Eingeleitet | Guggenheim | Buy |
| 2024-11-11 | Herabstufung | Stifel | Buy → Hold |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-08-12 | Eingeleitet | Piper Sandler | Neutral |
| 2024-07-09 | Eingeleitet | BofA Securities | Buy |
| 2024-07-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-07-09 | Eingeleitet | Longbow | Buy |
| 2024-07-09 | Eingeleitet | Loop Capital | Buy |
| 2024-07-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-07-09 | Eingeleitet | Needham | Buy |
| 2024-07-09 | Eingeleitet | Stifel | Buy |
| 2024-07-09 | Eingeleitet | TD Cowen | Buy |
| 2024-07-09 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Tempus Ai Inc Aktie (TEM) Neueste Nachrichten
Tempus AI, Inc. $TEM Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform - simplywall.st
Tempus AI Inc (TEM) Shares Down 5.14% on Mar 12 - GuruFocus
Top Artificial Intelligence Stocks To Watch NowMarch 12th - MarketBeat
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics - Yahoo Finance
First Trust Advisors LP Has $47.63 Million Position in Tempus AI, Inc. $TEM - MarketBeat
Cathie Wood’s ARK sells LY Corp stock, buys Tempus AI - Investing.com
Promising Artificial Intelligence Stocks To Follow TodayMarch 11th - MarketBeat
Why Tempus AI Stock Is Up Wednesday? - Benzinga
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings - Business Wire
Tempus AI: Underappreciated Oncology Platform and Data Business Poised for Reimbursement Upside and AI-Driven Growth - TipRanks
Tempus AI Earnings Call Highlights Strong Growth Path - TipRanks
Hims and Hers Expands Consumer-Focused Digital Health Platform - The Globe and Mail
Best Artificial Intelligence Stocks To Watch TodayMarch 10th - MarketBeat
H.C. Wainwright raises Tempus AI stock price target on partnerships - Investing.com
Best Artificial Intelligence Stocks Worth WatchingMarch 9th - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Tempus AI (NASDAQ:TEM) Stock - MarketBeat
Tempus AI Inc (TEM) Stock Price Down 3.2% on Mar 9 - GuruFocus
Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026? - The Globe and Mail
Should You Consider Purchasing, Retaining, or Selling Tempus AI Shares as 2026 Approaches? - Bitget
Assessing Tempus AI (TEM) Valuation After Expanded Merck Collaboration Announcement - Yahoo Finance
Tempus AI Deepens Merck Collaboration As Pharma Demand And Losses Evolve - Yahoo Finance
Artificial Intelligence Stocks To Keep An Eye OnMarch 7th - MarketBeat
Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine - Insider Monkey
Top Artificial Intelligence Stocks To Follow TodayMarch 6th - MarketBeat
Merck’s Oncology Pipeline Progress And Valuation Gap After Tempus AI Deal - Sahm
AI-Powered Tempus Inks New Multi-Year Merck Deal - Yahoo Finance Singapore
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? - TradingView
TD Asset Management Inc Takes Position in Tempus AI, Inc. $TEM - MarketBeat
ARK Investment Management LLC Has $579.16 Million Position in Tempus AI, Inc. $TEM - MarketBeat
Amova Asset Management Americas Inc. Has $279.47 Million Stake in Tempus AI, Inc. $TEM - MarketBeat
Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now? - Insider Monkey
Director David R. Epstein sells Tempus AI (TEM) shares under 10b5-1 plan - Stock Titan
Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era - The Cancer Letter
Tempus’ growth can’t shake Wall Street’s worries - Crain's Chicago Business
What Does the Market Think About Tempus AI Inc? - Benzinga
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings - AOL.com
TEM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tempus AI expands collaboration with Merck on precision medicine By Investing.com - Investing.com Australia
Merck’s Oncology Results And Tempus AI Deal Reframe Post Keytruda Future - simplywall.st
Top Artificial Intelligence Stocks To Add to Your WatchlistMarch 3rd - MarketBeat
Morgan Stanley Lowers Price Target for Tempus AI (TEM) to $70 | - GuruFocus
Tempus AI (NASDAQ:TEM) Price Target Lowered to $70.00 at Morgan Stanley - MarketBeat
Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes - Benzinga
Merck (MRK) Partners with Tempus AI for Precision Oncology Advan - GuruFocus
Merck to collaborate with Tempus AI on precision oncology - Seeking Alpha
Tempus AI, Inc. Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine - marketscreener.com
Tempus announces strategic collaboration agreement with Merck to accelerate AI-driven precision medicine - marketscreener.com
Tempus AI, Merck Collaborate on AI-Driven Precision Medicine - marketscreener.com
Tempus AI expands collaboration with Merck on precision medicine - Investing.com India
Tempus Announces Strategic Collaboration Agreement With Merck To Accelerate Ai-Driven Precision Medicine - TradingView
Finanzdaten der Tempus Ai Inc-Aktie (TEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
1.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):